These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23573659)

  • 1. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
    Mandel S; Weinreb O; Youdim MB
    Drug Discov Today; 2004 Dec; 9(24 Suppl):S37-44. PubMed ID: 23573659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
    Mandel S; Weinreb O; Youdim MB
    Trends Pharmacol Sci; 2003 Apr; 24(4):184-91. PubMed ID: 12707005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
    Singh MP; Patel S; Dikshit M; Gupta YK
    Indian J Biochem Biophys; 2006 Apr; 43(2):69-81. PubMed ID: 16955754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
    Aviles-Olmos I; Limousin P; Lees A; Foltynie T
    Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and challenges in the dosage form design for the treatment of Parkinson's disease.
    Wen MM
    Discov Med; 2012 Dec; 14(79):369-77. PubMed ID: 23272689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA microarrays in drug discovery and development.
    Debouck C; Goodfellow PN
    Nat Genet; 1999 Jan; 21(1 Suppl):48-50. PubMed ID: 9915501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective therapy for Parkinson's disease.
    Koller WC
    Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling of Parkinson's disease in mice.
    Chesselet MF; Richter F
    Lancet Neurol; 2011 Dec; 10(12):1108-18. PubMed ID: 22094131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    Hung AY; Schwarzschild MA
    Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain on a chip: a method to detect novel neuroprotective candidate targets.
    Tang Y; Bernaudin M
    Methods Mol Biol; 2007; 399():153-66. PubMed ID: 18309931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
    Meissner W; Hill MP; Tison F; Gross CE; Bezard E
    Trends Pharmacol Sci; 2004 May; 25(5):249-53. PubMed ID: 15120490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and neurorestorative strategies for Parkinson's disease.
    Dawson TM; Dawson VL
    Nat Neurosci; 2002 Nov; 5 Suppl():1058-61. PubMed ID: 12403986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB; Geldenhuys WJ; Van der Schyf CJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.